Referentielijst

Abdulla A (2013)
Abdulla, A., Adams, N., Bone, M., Elliott, A. M., Gaffin, J., Jones, D., ... & Schofield, P. (2013). Guidance on the management of pain in older people. Age and ageing, 42, i1-57. 

Ahmedzai S (1997)
Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997;13:254-61.

Ahmedzai SH (2010)
Ahmedzai SH, Boland J. Constipation in people prescribed opioids. BMJ Clin Evid. 2010; 2010. pii: 2407.

Alemzadeh-Ansari MJ (2017)
Alemzadeh-Ansari MJ, Ansari-Ramandi MM, Naderi N. Chronic pain in chronic heart failure: a review article. J Tehran Heart Cent 2017; 12(2): 49-56.

Ashby M (1997)
Ashby, M., Fleming, B., Wood, M., & Somogyi, A. (1997). Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. Journal of pain and symptom management, 14(3), 157–167. https://doi-org.saz.idm.oclc.org/10.1016/S0885-3924(97)00020-1.

Ashley C (2019)
Ashley, C., & Dunleavy, A. (2019). The Renal Drug Handbook (5th Edition). Taylor & Francis Group. https://medicinainterna.net.pe/sites/default/files/The_Renal_Drug_Handbook_The_Ultimate.pdf.

Baldo BA (2020)
Baldo, B. A., & Rose, M. A. (2020). The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. British journal of anaesthesia, 124(1), 44–62. https://doi.org/10.1016/j.bja.2019.08.010.

Barrett BJ (1996)
Barrett, B. J. (1996). Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. American journal of kidney diseases, 28(1), S14-S19.

Beernaert K (2013)
Beernaert K, Cohen J, Deliens L, et al. Referral to palliative care in COPD and other chronic diseases: a population-based study. Respir Med 2013;107(11):1731-9.

Bhattarai P (2016)
Bhattarai P, Hickman L, Phillips JL. Pain among hospitalized older people with heart failure and their preparation to manage this symptom on discharge: a descriptive-observational study. Contemp Nurse 2016; 52: 204-215.

Blantz R. C. (1996). Acetaminophen: acute and chronic effects on renal function. American journal of kidney diseases: the official journal of the National Kidney Foundation, 28(1 Suppl 1), S3–S6. https://doi-org.saz.idm.oclc.org/10.1016/s0272-6386(96)90561-2.
Blantz RC (1996)

Blum RA (1994)
Blum, R. A., Comstock, T. J., Sica, D. A., Schultz, R. W., Keller, E., Reetze, P., Bockbrader, H., Tuerck, D., Busch, J. A., & Reece, P. A. (1994). Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clinical pharmacology and therapeutics, 56(2), 154–159. https://doi-org.saz.idm.oclc.org/10.1038/clpt.1994.118.

Bockbrader HN (2010)
Bockbrader, H. N., Radulovic, L. L., Posvar, E. L., Strand, J. C., Alvey, C. W., Busch, J. A., ... & Wesche, D. L. (2010). Clinical pharmacokinetics of pregabalin in healthy volunteers. The Journal of Clinical Pharmacology, 50(8), 941-950.

Bookwalter T (2005)
Bookwalter, T., & Gitlin, M. (2005). Gabapentin-induced neurologic toxicities. Pharmacotherapy, 25(12), 1817–1819. https://doi-org.saz.idm.oclc.org/10.1592/phco.2005.25.12.1817.

Bootsma J (2019)
Bootsma, J. E., Cornelissen, P., & van Marum, R. J. (2019). Medicamenteuze behandeling van pijn bij ouderen: 10 tips vanuit de klinische farmacologie. Nederlands Tijdschrift voor Geneeskunde, 163(7), D2984.

Borge CR (2011)
Borge CR, Wahl AK, Moum T. Pain and quality of life with chronic obstructive pulmonary disease. Heart & Lung 2011; 40: E90-E101.

Brater DC (1983)
Brater, D. C., & Chennavasin, P. (1983). Drug use in renal disease. ADIS Health Science Press.

Brater DC (1985)
Brater, D. C., Anderson, S., Baird, B., & Campbell, W. B. (1985). Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney international, 27(1), 66-73.

Caparrotta TM (2018)
Caparrotta TM, Antoine DJ, Dear JW. Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. Eur J Clin Pharmacol. 2018;74(2):147-160. doi:10.1007/s00228-017-2356-6.

Caraceni A (2004)
Caraceni, A., Zecca, E., Bonezzi, C., Arcuri, E., Tur, R. Y., Maltoni, M., ... & Barbieri, M. (2004). Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Journal of clinical oncology, 22(14), 2909-2917.

Cattermole GN (2009)
Cattermole GN, Graham CA. Opiates should be avoided in acute decompensated heart failure. Emerg Med J 2009 Mar; 26 (3): 230-1.

Chan FK (2017)
Chan, F. K., Ching, J. Y., Tse, Y. K., Lam, K., Wong, G. L., Ng, S. C., ... & Kyaw, M. H. (2017). Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. The Lancet, 389(10087), 2375-2382.

Chang VT (2006)
Chang VT, Janjan N, Jain S, et al. Update in cancer pain syndromes. J Palliat Med 2006; 9: 1414-1434. # https://www.ncbi.nlm.nih.gov/pubmed/17187550

Chen YW (2017)
Chen YW, Camp PG, Coxson HO, et al. Comorbidities that cause pain and the contributors to pain in individuals with chronic obstructive pulmonary disease. Arch Phys Med Rehab 2017; 98: 1535-1543.

Cherny N (2001)
Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.

Chey WD (2014)
Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain.N Engl J Med. 2014; 370: 2387-2396.

Clark AJ (2004)
Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oralmorphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28.

Clemens KE (2009)
Clemens, K. E., & Klaschikl, E. (2009). Morphine and hydromorphone in palliative care patients with renal impairment. ANASTHESIOLOGIE & INTENSIVMEDIZIN, 50, 70-+.

Cope DG (2019)
Cope D.G. (2019). Cancer Pain Management Considerations in Older Adults. Seminars in oncology nursing, 35(3), 274–278. https://doi-org.saz.idm.oclc.org/10.1016/j.soncn.2019.04.008.

Dale O (2010)
Dale O, Moksnes K, Kaasa S. European Palliatieve Care Research collaborative pain guidelines. Opioid switching to improve analgesia or seduce side effcts. A systematic review. Palliat Med 2010; 25: 494-503.

Dam van Isselt van EF (2014)
Dam van Isselt van EF, Groenewegen-Sipkema KH, Spruit-van Eijk M, Chavannes NH, de Waal MW, Janssen DJ, Achterberg WP. Pain in patients with COPD: a systematic review and meta-analysis. BMJ Open 2014; 4(9): e005898.

Davies A (2011)
Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011; 13: 756-763

Davies AN (2009)
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009; 13(4): 331-8. # https://www.ncbi.nlm.nih.gov/pubmed/18707904

Davies NM (2000)
Davies, N. M., & Skjodt, N. M. (2000). Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clinical pharmacokinetics, 38(5), 377–392. https://doi-org.saz.idm.oclc.org/10.2165/00003088-200038050-00001.

Davison SN (2019)
Davison, S. N. (2019). Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clinical Journal of the American Society of Nephrology,14(6),917-931.

Dean M (2004)
Dean, M. (2004). Opioids in renal failure and dialysis patients. Journal of pain and symptom management, 28(5), 497-504.

Derry S (2017)
Derry, S., Wiffen, P. J., Moore, R. A., McNicol, E. D., Bell, R. F., Carr, D. B., ... & Wee, B. (2017). Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews, (7). Drug and therapeutics bulletin (2018). What dose of paracetamol for older people? 56(6), 69–72. https://doi-org.saz.idm.oclc.org/10.1136/dtb.2018.6.0636.

Dogukan A (2006)
Dogukan, A., Aygen, B., Berilgen, M. S., Dag, S., Bektas, S., & Gunal, A. I. (2006). Gabapentin-induced coma in a patient with renal failure. Hemodialysis international. International Symposium on Home Hemodialysis, 10(2), 168–169. https://doi-org.saz.idm.oclc.org/10.1111/j.1542-4758.2006.00089.x.

Durand JP (2012)
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin‐induced acute neurotoxicity: results of EFFOX, a randomized, double‐blind, placebo‐controlled phase III trial. Annals of Oncology 2012;23(1):200‐5.

Durnin C (2001)
Durnin, C., Hind, I. D., Ghani, S. P., Yates, D. B., & Molz, K. H. (2001). Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proceedings of the Western Pharmacology Society, 44, 83–84.

Eizenga WH (2006)
Eizenga WH, De Bont M, Vriezen JA, et al. METC. Landelijke eerstelijns samenwerkingsafspraak palliatieve zorg. Huisarts en Wetenschap 2006; 49: 308-312.

Els C (2017)
Els C, Jackson TD. Kuny D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Syst Rev 2017; 10: CD012509.

EPHOR (2013a)
EPHOR (2013a). Opioïden ‘Geneesmiddelbeoordeling voor de kwetsbare oude patiënt in het Farmacotherapeutisch Kompas’. Geraadpleegd op 19 oktober 2020, van https://ephor.nl/wp-content/uploads/Opioiden-versie-2-Ephor-april-2013-.pdf.

EPHOR (2013b)
EPHOR (2013b). Tricyclische antidepressivia ‘Geneesmiddelbeoordeling voor de kwetsbare oude patiënt in het Farmacotherapeutisch Kompas’. Geraadpleegd op 19 oktober 2020, van https://ephor.nl/wp-content/uploads/2018/12/tricyclische-antidepressive-rapport-2013.pdf.

EPHOR (2014)
EPHOR (2014). NSAID’s ‘Geneesmiddelbeoordeling voor de kwetsbare oude patiënt in het Farmacothera(eutisch Kompas’. Geraadpleegd op 19 oktober 2020, van https://ephor.nl/wp-content/uploads/2018/12/nsaid_rapport_herziene_versie_280114bde0.pdf.

EPHOR (2019)
EPHOR (2019). Serotonine heropnameremmers en andere tweede generatie antidepressiva ‘Geneesmiddelbeoordeling voor de (kwetsbare) oude patiënt’. Geraadpleegd op 19 oktober 2020, van https://ephor.nl/wp-content/uploads/2018/12/sris-rapport-2012.pdf.

Evangelista LS (2009)
Evangelista LS, Sackett E, Dracup K. Pain and heart failure: unrecognized and untreated. Eur J Carciovasc Nursing 2009; 8: 169-173.

Evans M (2009)
Evans, M., Fored, C. M., Bellocco, R., Fitzmaurice, G., Fryzek, J. P., McLaughlin, J. K., ... & Elinder, C. G. (2009). Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrology Dialysis Transplantation, 24(6), 1908-1918.

Fallon M (2018)
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., Ripamonti, C. I., & ESMO Guidelines Committee (2018). Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of oncology: official journal of the European Society for Medical Oncology, 29 Suppl 4, iv166–iv191. https://doi-org.saz.idm.oclc.org/10.1093/annonc/mdy152 .

Farmacotherapeutisch Kompas. (z.d.-a)
Farmacotherapeutisch Kompas. (z.d.-a). Paracetamol. Geraadpleegd 8 september 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/groepsteksten/nsaid_s__overige.

Farmacotherapeutisch Kompas. (z.d.-b)
Farmacotherapeutisch Kompas. (z.d.-b). NSAID’s. Geraadpleegd 8 september 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/groepsteksten/nsaid_s__overige.

Farmacotherapeutisch Kompas. (z.d.-c)
Farmacotherapeutisch Kompas. (z.d.-c). Morfine. Geraadpleegd 1 september 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/m/morfine

Farmacotherapeutisch Kompas. (z.d.-d)
Farmacotherapeutisch Kompas. (z.d.-d). Oxycodon. Geraadpleegd 21 juli 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/o/oxycodon.

Farmacotherapeutisch Kompas. (z.d.-e)
Farmacotherapeutisch Kompas. (z.d.-e). Fentanyl. Geraadpleegd 1 september 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/f/fentanyl__transdermaal_#eigenschappen.

Farmacotherapeutisch Kompas. (z.d.-f)
Farmacotherapeutisch Kompas. (z.d.-f). Hydromorfon. Geraadpleegd 21 juli 2020, van www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/h/hydromorfon.

Farmacotherapeutisch Kompas. (z.d.-g)
Farmacotherapeutisch Kompas. (z.d.-g). Methadon. Geraadpleegd 21 juli 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/m/methadon.

Farmacotherapeutisch Kompas. (z.d.-h)
Farmacotherapeutisch Kompas. (z.d.-h). Tapentadol. Geraadpleegd 3 september 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/tapentadol.

Farmacotherapeutisch Kompas. (z.d.-i)
Farmacotherapeutisch Kompas. (z.d.-i). Amitriptyline. Geraadpleegd 18 oktober 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/a/amitriptyline.

Farmacotherapeutisch Kompas. (z.d.-j)
Farmacotherapeutisch Kompas. (z.d.-j). Nortriptyline. Geraadpleegd 18 oktober 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/n/nortriptyline.

Farmacotherapeutisch Kompas. (z.d.-k)
Farmacotherapeutisch Kompas. (z.d.-k). Duloxetine. Geraadpleegd 17 december 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/d/duloxetine.

Farmacotherapeutisch Kompas. (z.d.-l)
Farmacotherapeutisch Kompas. (z.d.-l). Venlafaxine. Geraadpleegd 17 december 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/v/venlafaxine.

Farmacotherapeutisch Kompas. (z.d.-m)
Farmacotherapeutisch Kompas. (z.d.-m). Pregabaline. Geraadpleegd 5 november 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/p/pregabaline.

Farmacotherapeutisch Kompas. (z.d.-n)
Farmacotherapeutisch Kompas. (z.d.-n). Gabapentine. Geraadpleegd 5 november 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/g/gabapentine.

Farmacotherapeutisch Kompas. (z.d.-o)
Farmacotherapeutisch Kompas. (z.d.-o). Buprenorfine. Geraadpleegd 2 mei 2021, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/b/buprenorfine#bijwerkingen.

Farmacotherapeutisch Kompas. (z.d.-p)
Farmacotherapeutisch Kompas. (z.d.-p). Tricyclische antidepressivia. Geraadpleegd 19 oktober 2020, van https://www.farmacotherapeutischkompas.nl/bladeren/groepsteksten/tricyclische_antidepressiva

Farmacotherapeutisch Kompas. (z.d.-q)
Farmacotherapeutisch Kompas. (z.d.-q). Corticosteroïden. Geraadpleegd 8 september 2020 van https://www.farmacotherapeutischkompas.nl/bladeren/groepsteksten/corticosteroiden__systemisch.

Ferro C (2004)
Ferro, C., Chambers, J., & Davison, S. (2004). Management of pain in renal failure. In Supportive Care for the Renal Patient (pp. 105-142). Oxford University Press, Oxford, UK.

Filitz J (2006)
Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006 Nov;10(8):743-8. doi: 10.1016/j.ejpain.2005.12.001. Epub 2006 Jan 19. PMID: 16426877.

Finnerup NB (2016)
Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016; 157:1599-1606.

Fitzgerald J (1991)
Fitzgerald J. (1991). Narcotic analgesics in renal failure. Connecticut medicine, 55(12), 701–704.

Foral PA (2007)
Foral, P. A., Ineck, J. R., & Nystrom, K. K. (2007). Oxycodone accumulation in a hemodialysis patient. Southern medical journal, 100(2), 212–214. https://doi-org.saz.idm.oclc.org/10.1097/01.smj.0000242876.45747.0a.

Gardiner C (2010)
Gardiner C, Gott M, Payne S, et al. Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med 2010;104(2):159-65.

Ghannoum M (2016)
Ghannoum, M., Kazim, S., Grunbaum, A. M., Villeneuve, E., & Gosselin, S. (2016). Massive acetaminophen overdose: effect of hemodialysis on acetaminophen and acetylcysteine kinetics. Clinical Toxicology, 54(6), 519-522.

Godfrey C (2006)
Godfrey C, Harrison MB, Medves J, Tranmer JE. The symptom of pain with heart failure: a systematic review. J Card Fail 2006; 12(4): 307-13.

Golf M (2004)
Golf M, Paice JA, Feulner E, O'Leary C, Marcotte S, Mulcahy M. Refractory status epilepticus. J Palliat Med. 2004 Feb;7(1):85-8. doi: 10.1089/109662104322737331. PMID: 15000791.

Goodlin SJ (2012)
Goodlin SJ, Wingate S, Albert NM, et L. Investigating pain in heart failure patients: the pain assessment, incidence, and nature in heart failure (PAIN-HF) Study.J Cardiac Faiure 2012; 18: 776-783.

Gore JM (2000)
Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55(12):1000-6.

Graeff A de (2006)
Graeff A de, Krol RJA. Richtlijn obstipatie. In: Graeff A de, Hesselmann GM, Krol RJA, et al. Richtlijnen voor de praktijk. Utrecht: Vereniging voor Integrale Kankercentra, 2006;b:521-36.

HajGhanbari B (2014)
HajGhanbari B, Yamabayashi C, Garland SJ, Road JD, Reid WD. The relationship between pain and comorbid health conditions in people with chronic obstructive pulmonary disease. Cardiopulm Phys Ther J 2014; 25: 29-35.

Hand CW (1990)
Hand, C. W., Sear, J. W., Uppington, J., Ball, M. J., McQuay, H. J., & Moore, R. A. (1990). Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. British journal of anaesthesia, 64(3), 276–282. https://doi-org.saz.idm.oclc.org/10.1093/bja/64.3.276.

Hartrick CT (2011)
Hartrick, C. T., & Rozek, R. J. (2011). Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS drugs, 25(5), 359–370. https://doi-org.saz.idm.oclc.org/10.2165/11589080-000000000-00000.

Haywood A (2015)
Haywood, A., Good, P., Khan, S., Leupp, A., Jenkins-Marsh, S., Rickett, K., & Hardy, J. R. (2015). Corticosteroids for the management of cancer-related pain in adults. The Cochrane database of systematic reviews, (4), CD010756. https://doi-org.saz.idm.oclc.org/10.1002/14651858.CD010756.pub2.

Heiskanen T (2009)
Heiskanen, T., Mätzke, S., Haakana, S., Gergov, M., Vuori, E., & Kalso, E. (2009). Transdermal fentanyl in cachectic cancer patients. Pain, 144(1-2), 218–222. https://doi.org/10.1016/j.pain.2009.04.012.

Henry D (1997)
Henry, D., Page, J., Whyte, I., Nanra, R., & Hall, C. (1997). Consumption of non‐steroidal anti‐inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case‐control study. British journal of clinical pharmacology, 44(1), 85-90.

IASP (1994)
IASP. Task force on taxonomy. Classification of chronic pain. Seattle: IASP Press, 1994

IASP (2008)
IASP. Total cancer pain, 2008.

IKNL (2017)
IKNL (2017). Palliatieve zorg bij eindstadium nierfalen. https://richtlijnendatabase.nl/richtlijn/nierfalen/organisatie_van_zorg/starten_staken_dialyse.html.

IKNL/Palliactief (2017)
IKNL/Palliactief 2017, Kwaliteitskader palliatieve zorg Nederland, 2017.

Imanaka K (2013)
Imanaka, K., Tominaga, Y., Etropolski, M., van Hove, I., Ohsaka, M., Wanibe, M., Hirose, K., & Matsumura, T. (2013). Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current medical research and opinion, 29(10), 1399–1409. https://doi-org.saz.idm.oclc.org/10.1185/03007995.2013.831816.

Imanaka, K., Tominaga, Y., Etropolski, M., Ohashi, H., Hirose, K., & Matsumura, T. (2014). Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical drug investigation, 34(7), 501–511. https://doi.org/10.1007/s40261-014-0204-3.
Imanaka K (2014)

Janssen DJ (2008)
Janssen DJ, Spruit MA, Wouters EF, Schols JM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med 2008; 22,938-948.

Joshi M (2012)
Joshi M, Joshi A, Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr Opin Pulm Med 2012;18(2):97-103.

Kaiko R (1996)
Kaiko, R., Benziger, D., Cheng, C., Hou, Y., & Grandy, R. (1996). Clinical Pharmacokinetics of Controlled‐Release Oxycodone in Renal Impairment. Clinical Pharmacology&Therapeutics,59(2),130-130.

Kanchanasurakit S (2020)
Kanchanasurakit S, Arsu A, Siriplabpla W, Duangjai A, Saokaew S. Acetaminophen use and risk of renal impairment: A systematic review and meta-analysis. Kidney Res Clin Pract. 2020 Mar 31;39(1):81-92. doi: 10.23876/j.krcp.19.106. PMID: 32172553; PMCID: PMC7105620.

Kato H (2015)
Kato, H., Miyazaki, M., Takeuchi, M., Tsukuura, H., Sugishita, M., Noda, Y., & Yamada, K. (2015). A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin. Journal of pharmaceutical health care and sciences, 1, 22. https://doi-org.saz.idm.oclc.org/10.1186/s40780-015-0022-7.

King S (2011)
King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine, 25(5), 525-552.

Kirvela M (1996)
Kirvela, M., Lindgren, L., Seppala, T., & Olkkola, K. T. (1996). The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. Journal of clinical anesthesia, 8(1), 13-18.

Klepstad P (2003)
Klepstad, P., Dale, O., Kaasa, S., Zahlsen, K., Aamo, T., Fayers, P., & Borchgrevink, P. C. (2003). Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. Acta anaesthesiologica Scandinavica, 47(6), 725–731. https://doi-org.saz.idm.oclc.org/10.1034/j.1399-6576.2003.00138.x.

KNMP Kennisbank (2019)
KNMP Kennisbank 2019.

KNMP Kennisbank. (z.d.) (2020)
KNMP Kennisbank. (z.d.). Actuele vakinhoudelijke informatie voor de apotheker en het apotheekteam. Geraadpleegd 1 december 2020 van https://kennisbank.knmp.nl/login?destination=.

Kreek MJ (1980)
Kreek, M. J., Schecter, A. J., Gutjahr, C. L., & Hecht, M. (1980). Methadone use in patients with chronic renal disease. Drug and alcohol dependence, 5(3), 197–205. https://doi-org.saz.idm.oclc.org/10.1016/0376-8716(80)90180-5.

Kress HG (2014)
Kress, H. G., Koch, E. D., Kosturski, H., Steup, A., Karcher, K., Lange, B., Dogan, C., Etropolski, M. S., & Eerdekens, M. (2014). Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain physician, 17(4), 329–343.

Kuip E (2018)
Kuip, E., Oldenmenger, W. H., Thijs-Visser, M. F., de Bruijn, P., Oosten, A. W., Oomen-de Hoop, E., Koolen, S., Van der Rijt, C., & Mathijssen, R. (2018). Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. PloS one, 13(6), e0198289. https://doi-org.saz.idm.oclc.org/10.1371/journal.pone.0198289.

Kurita GP (2015)
Kurita, G. P., Lundström, S., Sjøgren, P., Ekholm, O., Christrup, L., Davies, A., Kaasa, S., Klepstad, P., & Dale, O. (2015). Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta anaesthesiologica Scandinavica, 59(8), 1049–1059. https://doi-org.saz.idm.oclc.org/10.1111/aas.12521.

Laugsand EA (2011)
Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442-53.

Launay-Vacher V (2005)
Launay-Vacher, V., Karie, S., Fau, J. B., Izzedine, H., & Deray, G. (2005). Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted. The Journal of pain, 6(3), 137-148.

Lee A L (2015)
Lee A L, Harrison SL, Goldstein RS, Brooks D. Pain and its clinical associations in individuals with COPD: a systematic review. Chest 2015; 147: 1246-1258.

Lee M (2011)
Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14(2): 145-61.

Lee MA (2001)
Lee, M. A., Leng, M. E., & Tiernan, E. J. (2001). Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliative medicine, 15(1), 26–34. https://doi-org.saz.idm.oclc.org/10.1191/026921601669626431.

Light-McGroary KA (2013)
Light-McGroary KA, Goodlin SJ. The challenges of understanding and managing pain in the heart failure patiënt. Curr Opinion 2013; 7: 14-20.

Loeser JD (1989)
Loeser JD, In Seitz FC, JCarr JE, Covey M (Eds.): Issues in behavioral medicine. Bozema, MT: Clinical Management Consultants, 1989, pp. 16-20.

Loeser JD (1999)
Loeser JD, Melzack R. Pain: an overview. The Lancet 1999: 1607-1609.

Lopez-Saca JM (2013)
Lopez-Saca JM, Lopez Guzman J, Centena C. A systematic review of the influence of opioids on advanced cancer patient survival. Curr opinion 2013; 7 ; 424-439.

Malec M (2015)
Malec M, Shega JW. Pain management in the elderly. Med Clin North Am. 2015;99(2):337-350. doi:10.1016/j.mcna.2014.11.007.

Malec M (2019)
Malec, M., & Levine, S. (2019). How do I best treat pain in my older patient with cancer?. Journal of geriatric oncology, 10(6), 841–844. https://doi-org.saz.idm.oclc.org/10.1016/j.jgo.2019.05.009.

Mazzocato C (2006)
Mazzocato, C., Beauverd, M., & Anwar, D. (2006). Subcutaneous fentanyl in severely ill patients with renal failure. Palliative Medicine, 20(3), 301-302.

McCaffery M (1968)
McCaffery, M. Nursing practice theories related to cognition, bodily pain, and man-environment interactions. University of California at Los Angeles Students’ Store, Los Angeles; 1968.

McLachlan AJ (2011)
McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Br J Clin Pharmacol. 2011;71:351-64. doi:10.1111/j.1365-2125.2010.03847.x.

McNicol E (2003)
McNicol E, Horowicz-Mehler N, Fisk R, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56.

McNicol E (2008)
McNicol E. Opioid side effects and their treatment in patients with chronic cancer and noncancer pain. J Pain Palliat Care Pharmacotherapy. 2008; 22(4): 270-81.

Mehta N (2016)
Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016;128(3): 282-9.

Mercadante S (1997)
Mercadante, S., Caligara, M., Sapio, M., Serretta, R., & Lodi, F. (1997). Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. Journal of pain and symptom management, 13(4), 241–244. https://doi-org.saz.idm.oclc.org/10.1016/s0885-3924(97)00076-6.

Mercadante S (2001)
Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and toler-ability in cancer patients. A prospective study. J Clin Oncol 2001;19:2898-904.

Mercadante S (2008)
Mercadante, S., Porzio, G., Ferrera, P., Fulfaro, F., Aielli, F., Verna, L., ... & Casuccio, A. (2008). Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 12(8), 1040-1046.

Mian P (2018)
Mian P, Allegaert K, Spriet I, Tibboel D, Petrovic M. Paracetamol in Older People: Towards Evidence-Based Dosing?. Drugs Aging. 2018;35(7):603-624. doi:10.1007/s40266-018-0559-x.

Miller A (2009)
Miller, A., & Price, G. (2009). Gabapentin toxicity in renal failure: the importance of dose adjustment. Pain medicine (Malden, Mass.), 10(1), 190–192. https://doi-org.saz.idm.oclc.org/10.1111/j.1526-4637.2008.00492.x.

Moore S (2002)
Moore S, Corner J, Haviland J, et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002; 325: 1-7.

Narabayashi M (2008)
Narabayashi, M., Saijo, Y., Takenoshita, S., Chida, M., Shimoyama, N., Miura, T., Tani, K., Nishimura, K., Onozawa, Y., Hosokawa, T., Kamoto, T., Tsushima, T., & Advisory Committee for Oxycodone Study (2008). Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Japanese journal of clinical oncology, 38(4), 296–304. https://doi-org.saz.idm.oclc.org/10.1093/jjco/hyn010.

NHG (2018)
NHG (2018). NHG-Standaard Pijn, actualisering juni 2018. Utrecht: NHG; 2018.

NHG/NIV (2018)
NHG/NIV (2018). Chronische nierschade (CNS). https://richtlijnendatabase.nl/richtlijn/chronische_nierschade_cns/startpagina_-_chronische_nierschade_cns.html.

Nicholson AB (2017)
Nicholson, A. B., Watson, G. R., Derry, S., & Wiffen, P. J. (2017). Methadone for cancer pain. The Cochrane database of systematic reviews, 2(2), CD003971. https://doi.org/10.1002/14651858.CD003971.pub4.

Nolte K (2015)
Nolte K, Herrmann-Lingen C, Wachter R, et al. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 2015; 22: 582-93.

NVA (2019)
NVA (2019). Pijn bij patiënten met kanker. https://richtlijnendatabase.nl/richtlijn/behandeling_van_pijn_bij_patienten_met_kanker/beleid_en_behandeling_bij_pijn_bij_kanker.html.

Oldenmenger WH (2006)
Oldenmenger WH, Stronks DL, Terwiel CTM, et al. Naar een landelijke, uniforme verpleegkundige Pijnanamnese. Psychometrische kwaliteiten. Nederlands Tijdschrift voor Pijnbestrijding 2006, nr 2: 2-6.

Oscanoa TJ (2017)
Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759-770. doi:10.1007/s00228-017-2225-3.

Pace MC (2007)
Pace, M. C., Passavanti, M. B., Grella, E., Mazzariello, L., Maisto, M., Barbarisi, M., Baccari, E., Sansone, P., & Aurilio, C. (2007). Buprenorphine in long-term control of chronic pain in cancer patients. Frontiers in bioscience : a journal and virtual library, 12, 1291–1299. https://doi.org/10.2741/2147

Pallialine (2010)
Pallialine (2010). Richtlijn Delier. Geraadpleegd 1 december 2020 van https://www.pallialine.nl/delier.

Paramanandam G (2011)
Paramanandam, G., Prommer, E., & Schwenke, D. C. (2011). Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. Journal of palliative medicine, 14(9), 1029–1033. https://doi-org.saz.idm.oclc.org/10.1089/jpm.2011.0103.

Peacock WF (2008)
Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008 Apr; 25 (4): 205-9

Piotrowicz E (2015)
Piotrowicz E, Stepnowska M, Leszczynska-Iwanicka K, et al. Quality of life in heart failure patiënts undergoing home-based telerehabilitation versus outpatient rehabilitation, a randomized controlled study. Eur J Cardiovasc Nursing 2015; 14: 256-63. 

Quigley C (2002)
Quigley C. (2002). Hydromorphone for acute and chronic pain. The Cochrane database of systematic reviews, (1), CD003447. https://doi.org/10.1002/14651858.CD003447

Randinitis EJ (2003)
Randinitis, E. J., Posvar, E. L., Alvey, C. W., Sedman, A. J., Cook, J. A., & Bockbrader, H. N. (2003). Pharmacokinetics of pregabalin in subjects with various degrees of renal function. The Journal of Clinical Pharmacology, 43(3), 277-283.

Raptis E (2014)
Raptis, E., Vadalouca, A., Stavropoulou, E., Argyra, E., Melemeni, A., & Siafaka, I. (2014). Pregabalin versus opioids for the treatment of neuropathic cancer pain: a prospective, head‐to‐head, randomized, open‐label study. Pain Practice, 14(1), 32-42.

Reid CM (2006)
Reid, C. M. , Martin, R. M. , Sterne, J. A. , Davies, A. N. & Hanks, G. W. (2006). Oxycodone for Cancer-Related Pain. Archives of Internal Medicine, 166(8), 837–843.

Riley J (2004)
Riley, J., Ross, J. R., Rutter, D., Shah, S., Gwilliam, B., Wells, A. U., & Welsh, K. (2004). A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliative medicine, 18(1), 19–24. https://doi-org.saz.idm.oclc.org/10.1191/0269216304pm856oa.

Riley J (2006)
Riley, J., Ross, J. R., Rutter, D., Wells, A. U., Goller, K., du Bois, R., & Welsh, K. (2006). No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 14(1), 56–64. https://doi-org.saz.idm.oclc.org/10.1007/s00520-005-0843-2.

Ruston T (2013)
Ruston T, Hunter K, Cummings G, Lazarescu L. Efficacy and side-effect profiles of lactulose, docusate sodium and sennosides compared to PEG in opioid-induced constipation: a systematic review. Can Oncol Nurs J. 2013; 23(4): 236-46.

Sande TA (2017)
Sande, T. A., Laird, B. J., & Fallon, M. T. (2017). The use of opioids in cancer patients with renal impairment—a systematic review. Supportive Care in Cancer, 25(2), 661-675.

Sande TA (2019)
Sande TA, Laird BJA, Fallon MT. The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med 2019; 22: 9097.

Saunders C (1984)
Saunders C. The philosophy of terminal care. In: Sunders C (ed). The management of terminal malignant illness. Baltimore MD: Arnold Publishers, 1984, pp 232-241.

Schofield P (2018)
Schofield, P. (2018). The assessment of pain in older people: UK national guidelines. Age and ageing, 47(suppl_1), i1-i22.

Schünemann H (2013)
Schünemann H, Brożek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html.

Sivanesan E (2016)
Sivanesan E, Gitlin MC, Candiotti KA. Opioid-induced Hallucinations: A Review of the Literature, Pathophysiology, Diagnosis, and Treatment. Anesthesia and analgesia. 2016;123(4):836-43.

Smith H (2010)
Smith, H., & Bruckenthal, P. (2010). Implications of opioid analgesia for medically complicated patients. Drugs & aging, 27(5), 417-433.

Somogyi AA (1993)
Somogyi, A. A., Nation, R. L., Olweny, C., Tsirgiotis, P., van Crugten, J., Milne, R. W., Cleary, J. F., Danz, C., & Bochner, F. (1993). Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clinical pharmacokinetics, 24(5), 413–420. https://doi-org.saz.idm.oclc.org/10.2165/00003088-199324050-00005.

Stone P (2011)
Stone P. Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med 2011; 25: 431-441.

Suno M (2015)
Suno, M., Endo, Y., Nishie, H., Kajizono, M., Sendo, T., & Matsuoka, J. (2015). Refractory cachexia is associated with increased plasma concentrations of fentanyl in cancer patients. Therapeutics and clinical risk management, 11, 751–757. https://doi.org/10.2147/TCRM.S79374.

Tassinari D (2008)
Tassinari, D., Sartori, S., Tamburini, E., Scarpi, E., Raffaeli, W., Tombesi, P., & Maltoni, M. (2008). Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. Journal of palliative medicine, 11(3), 492–501. https://doi.org/10.1089/jpm.2007.0200.

The Global Emergency Medicine Wiki (2019)
The Global Emergency Medicine Wiki. (2019). Dialyzable drugs. https://www.wikem.org/wiki/Dialyzable_drugs.

Thwaites D (2004)
Thwaites, D., McCann, S., & Broderick, P. (2004). Hydromorphone neuroexcitation. Journal of palliative medicine, 7(4), 545–550. https://doi-org.saz.idm.oclc.org/10.1089/jpm.2004.7.545.

Tiseo PJ (1995)
Tiseo, P. J., Thaler, H. T., Lapin, J., Inturrisi, C. E., Portenoy, R. K., & Foley, K. M. (1995). Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain, 61(1), 47–54. https://doi-org.saz.idm.oclc.org/10.1016/0304-3959(94)00148-8.

Toto RD (1986)
Toto, R. D., Anderson, S. A., Brown–Cartwright, D., Kokko, J. P., & Brater, D. C. (1986). Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency. Kidney international, 30(5), 760-768.

van Ojik AL (2012)
van Ojik, A. L., Jansen, P. A., Brouwers, J. R., & van Roon, E. N. (2012). Treatment of chronic pain in older people. Drugs & aging, 29(8), 615-625.

Verberkt CA (2017)
Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Resp J 2017; 52: pii: 1800882. doi: 10.1183/13993003.00882-2018.

Verenso (2016)
Verenso. (2016). Multidisciplinaire Richtlijn Pijn. Herkenning en behandeling van pijn bij kwetsbare ouderen Deel 1. https://www.verenso.nl/_asset/_public/Richtlijnen_kwaliteit/richtlijnen/database/VER-003-32-Richtlijn-Pijn-deel1-v5LR.pdf.

Volkow ND (2016)
Volkow ND, Mclellan AT. Opioid abuse in chronic pain - misconceptions and mitigation. N Engl J Med 2016; 374: 1253-1263.

Vollaard EJ (2014)
Vollaard EJ, Kramers C, Brouwers JR. Interactie NSAID’s en acetylsalicylzuur genegeerd. Ned Tijdschr Geneeskd. 2014;158:A7893.

Wiffen PJ (2017)
Wiffen PJ, Derry S, Moore RA, et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;7(7):CD012637. Published 2017 Jul 12. doi:10.1002/14651858.CD012637.pub2.

Wongrakpanich S (2018)
Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143-150. Published 2018 Feb 1. doi:10.14336/AD.2017.0306.

Wood MM (1998)
Wood, M. M., Ashby, M. A., Somogyi, A. A., & Fleming, B. G. (1998). Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. Journal of pain and symptom management, 16(2), 112–120. https://doi-org.saz.idm.oclc.org/10.1016/s0885-3924(98)00043-8.

Woolcott JC (2009)
Woolcott, J. C., Richardson, K. J., Wiens, M. O., Patel, B., Marin, J., Khan, K. M., & Marra, C. A. (2009). Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Archives of internal medicine, 169(21), 1952-1960.

Zand L (2010)
Zand, L., McKian, K. P., & Qian, Q. (2010). Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. The American journal of medicine, 123(4), 367–373. https://doi-org.saz.idm.oclc.org/10.1016/j.amjmed.2009.09.030.